DRKS00023619已完成未知
Retro- and prospective, single-center study to evaluate the safety and effectiveness 3 years after the XEN 45 stent implantation - XEN-Longterm-Study
Dietrich Bonhoeffer Klinikum, Klinik für Augenheilkunde0 个研究点目标入组 40 人开始时间: 2020年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 90 Years（—）
- 性别
- All
入选标准
- •Patients 2 to 5 years after implantation of a XEN 45 stent (2013-2018)
- •- Willingness of patients to participate in the study and written consent.
排除标准
- •- Patients with a distant place of residence or with a limited general condition due to illness, who cannot be expected to travel to Neubrandenburg.
- •- Patients who have moved unknown.
- •- Deceased patients (existing data are documented).
- •- Patients who are not interested in participating in the study
研究者
相似试验
进行中（未招募）
1 期
A multicenter, single-arm prospective study to determine safety and efficacy of GLE/PIB 8-week treatment in adults and adolescents acutely infected with hepatitis C virusEUCTR2020-005777-27-DEAbbVie Deutschland GmbH & Co. KG283
进行中（未招募）
1 期
A multicenter, single-arm prospective study to determine safety and efficacy of GLE/PIB 8-week treatment in adults and adolescents acutely infected with hepatitis C virusHepatitis C VirusMedDRA version: 20.1Level: PTClassification code 10065051Term: Acute hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005777-27-ITABBVIE DEUTSCHLAND GMBH & CO. KG283
进行中（未招募）
1 期
A multicenter, single-arm prospective study to determine safety and efficacy of GLE/PIB 8-week treatment in adults and adolescents acutely infected with hepatitis C virusHepatitis C VirusEUCTR2020-005777-27-ESAbbVie283
进行中（未招募）
1 期
A multicenter, single-arm prospective study to determine safety and efficacy of GLE/PIB 8-week treatment in adults and adolescents acutely infected with hepatitis C virusEUCTR2020-005777-27-ATAbbVie283
进行中（未招募）
1 期
A multicenter, single-arm prospective study to determine safety and efficacy of GLE/PIB 8-week treatment in adults and adolescents acutely infected with hepatitis C virusHepatitis C VirusEUCTR2020-005777-27-FRAbbVie Deutschland GmbH & Co.KG283